Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi

被引：13

作者：

Zaja, Francesco ^{[1
,2
]}

Salvi, Flavia ^{[3
]}

Rossi, Maura ^{[4
]}

Sabattini, Elena ^{[5
]}

Evangelista, Andrea ^{[5
]}

Ciccone, Giovannino ^{[6
,7
]}

Angelucci, Emanuele ^{[8
]}

Gaidano, Gianluca ^{[9
]}

Zanni, Manuela ^{[9
]}

Ladetto, Marco ^{[3
]}

Chiappella, Annalisa ^{[10
]}

Vitolo, Umberto ^{[10
]}

Zinzani, Pier Luigi ^{[11
]}

Califano, Catello ^{[12
]}

Tucci, Alessandra ^{[13
,14
]}

Patti, Caterina ^{[15
]}

Pileri, Stefano A. ^{[16
]}

Lenti, Valentina ^{[17
]}

Piccaluga, Pier Paolo ^{[4
]}

Cavallo, Federica ^{[18
]}

Volpetti, Stefano ^{[19
,20
]}

Perali, Giulia ^{[19
,20
]}

Assouline, Sarit ^{[21
]}

Mann, Koren Kathleen ^{[22
]}

Morin, Ryan ^{[23
]}

Alcaide, Miguel ^{[23
]}

Bushell, Kevin ^{[23
]}

Fanin, Renato ^{[1
,2
]}

Levis, Alessandro ^{[17
]}

机构：

[1] Univ Udine, Clin Ematol, DAME, Udine, Italy

[2] Univ Udine, Unita Terapie Cellulari Carlo Melzi, DAME, Udine, Italy

[3] AO SS Antonio & Biagio & C Arrigo, SC Ematol, Alessandria, Italy

[4] Univ Hosp Bologna, Unit Haemolymphopathol, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[5] Univ Hosp Bologna, Dept Hematol & Oncol, Unit Haemolymphopathol, Bologna, Italy

[6] AOU Citta Salute & Sci Torino, Unit Clin Epidemiol, Turin, Italy

[7] CPO Piemonte, Turin, Italy

[8] IRCCS AOU San Martino IST, UOC Ematol, Genoa, Italy

[9] Amedeo Avogadro Univ Eastern Piedmont, Dept Translat Med, Div Hematol, Novara, Italy

[10] AOU Citta Salute & Sci, SC Ematol, Turin, Italy

[11] Univ Bologna, Inst Hematol L&A Seragnoli, Bologna, Italy

[12] Osped Umberto I, UO Med Oncoematol, Nocera Inferiore, Italy

[13] Spedali Civil Brescia, SC Ematol, Brescia, Italy

[14] Spedali Civil Brescia, Dipartimento Oncol Med, Brescia, Italy

[15] Osped V Cervello, UOC Ematol, Palermo, Italy

[16] Milano Univ, Sch Med, European Inst Oncol, Haematopathol Unit, Bologna, Italy

[17] Fdn Italiana Linfomi, Alessandria, Italy

[18] Univ Torino, Azienda Osped Univ Citta Salute & Sci, Turin, Italy

[19] Azienda Sanit Univ Integrata, Clin Ematol, Udine, Italy

[20] Azienda Sanit Univ Integrata, Unita Terapie Cellulari Carlo Melzi, Udine, Italy

[21] McGill Univ, Jewish Gen Hosp, Div Hematol, Montreal, PQ, Canada

[22] McGill Univ, Lady Davis Inst, Jewish Gen Hosp, Montreal, PQ, Canada

[23] Simon Fraser Univ, Dept Mol Biol & Biochem, Sch Comp Sci, Vancouver, BC, Canada

来源：

LEUKEMIA & LYMPHOMA | 2018年 / 59卷 / 12期

关键词：

Diffuse large B-cell lymphoma; panobinostat; relapsed/refractory; genomic; DEACETYLASE INHIBITOR PANOBINOSTAT; HISTONE DEACETYLASES; RITUXIMAB; DISEASE; MULTICENTER; ROMIDEPSIN; MUTATION; LBH589; TRIAL; CHOP;

D O I：

10.1080/10428194.2018.1452208

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We investigated panobinostat 40 mg three times weekly in 35 adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Overall response rate and complete response were 17.1% and 11.4%, respectively. Median progression-free survival (PFS) and overall survival were 2.4 and 7.6 months, respectively. Calculated 12, 24 and 36 months PFS were 26%, 11% and 11%, respectively. Four patients who achieved a sustained CR, continued receiving panobinostat for an overall period of 44, 48, 50, 62 months. Thrombocytopenia grade 3 (5 patients) and 4 (24 patients) represented the main toxic effect, causing dose reduction or treatment suspension in 19 patients. Genomic analysis was unable to identify any relationship between mutations and response; TP53 mutation appeared not to impact the clinical outcome. Overall, panobinostat has a modest activity in R/R DLBCL patients, however it can induce very long lasting responses in some cases. Thrombocytopenia frequently limits the use of this agent.

引用

页码：2904 / 2910

页数：7

共 50 条

[31] Long-Term Follow-Up of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: Aims and Methodological Approach for Fondazione Italiana Linfomi Systematic Reviews
Gerardi, Chiara
Allocati, Eleonora
Minoia, Carla
Guarini, Attilio
Banzi, Rita
CANCERS, 2021, 13 (12)
[32] Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi
Storti, Sergio
Spina, Michele
Pesce, Emanuela Anna
Salvi, Flavia
Merli, Michele
Ruffini, Alessia
Cabras, Giuseppina
Chiappella, Annalisa
Angelucci, Emanuele
Fabbri, Alberto
Liberati, Anna Marina
Tani, Monica
Musuraca, Gerardo
Molinari, Annalia
Petrilli, Maria Pia
Palladino, Carmela
Ciancia, Rosanna
Ferrario, Andrea
Gasbarrino, Cristiana
Monaco, Federico
Fraticelli, Vincenzo
De Vellis, Annalisa
Merli, Francesco
Luminari, Stefano
HAEMATOLOGICA, 2018, 103 (08) : 1345 - 1350
[33] A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma
Collins, Graham P.
Eyre, Toby A.
Linton, Kim M.
Radford, John
Vallance, Grant D.
Soilleux, Elizabeth
Hatton, Chris
BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (06) : 886 - 890
[34] Clinical Efficacy and Safety in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Systematic Literature Review
Colosia, Ann
Njue, Annete
Trask, Peter C.
Olivares, Robert
Khan, Shahnaz
Abbe, Adeline
Police, Rachel
Wang, Jianmin
Ruiz-Soto, Rodrigo
Kaye, James A.
Awan, Farrukh
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (05) : 343 - 355
[35] Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma
Ward, Jeffrey P.
Berrien-Elliott, Melissa M.
Gomez, Felicia
Luo, Jingqin
Becker-Hapak, Michelle
Cashen, Amanda F.
Wagner-Johnston, Nina D.
Maddocks, Kami
Mosior, Matthew
Foster, Mark
Krysiak, Kilannin
Schmidt, Alina
Skidmore, Zachary L.
Desai, Sweta
Watkins, Marcus P.
Fischer, Anne
Griffith, Malachi
Griffith, Obi L.
Fehniger, Todd A.
Bartlett, Nancy L.
BLOOD, 2022, 139 (13) : 1999 - 2010
[36] Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma
Nastoupil, Loretta J.
Kuruvilla, John
Chavez, Julio C.
Bijou, Fontanet
Witzig, Thomas E.
Santoro, Armando
Flinn, Ian W.
Boccomini, Carola
Kenkre, Vaishalee P.
Corradini, Paolo
Isufi, Iris
Andorsky, David J.
Klein, Leonard M.
Greenwald, Daniel R.
Sangha, Randeep
Shen, Frank
Hagner, Patrick
Li, Yan
Dobmeyer, Juergen
Gong, Nian
Uttamsingh, Shailaja
Pourdehnad, Michael
Ribrag, Vincent
EJHAEM, 2022, 3 (02): : 394 - 405
[37] Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study
Palomba, M. Lia
Till, Brian G.
Park, Steven I.
Morschhauser, Franck
Cartron, Guillaume
Marks, Reinhard
Shivhare, Mahesh
Hong, Wan-Jen
Raval, Aparna
Chang, Alice C.
Penuel, Elicia
Popplewell, Leslie L.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07) : E443 - E451
[38] Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma
Kato, Koji
Makita, Shinichi
Goto, Hideki
Kanda, Junya
Fujii, Nobuharu
Shimada, Kazuyuki
Akashi, Koichi
Izutsu, Koji
Teshima, Takanori
Fukuda, Natsuko
Sumitani, Tokuhito
Sumi, Hiroyuki
Shimizu, Shinji
Kakurai, Yasuyuki
Yoshikawa, Kenji
Tobinai, Kensei
Usui, Noriko
Hatake, Kiyohiko
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (01) : 213 - 223
[39] Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group
Martin, Alejandro
Redondo, Alba M.
Dlouhy, Ivan
Salar, Antonio
Gonzalez-Barca, Eva
Canales, Miguel
Montes-Moreno, Santiago
Ocio, Enrique M.
Lopez-Guillermo, Armando
Caballero, Dolores
BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (02) : 245 - 252
[40] Glofitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and ≥2 Prior Therapies: Results From a Pivotal Phase II Expansion Study
Dickinson, Michael
Carlo-Stella, Carmelo
Morschhauser, Franck
Bachy, Emmanuel
Corradini, Paolo
Iacoboni, Gloria
Khan, Cyrus
Wrobel, Thomasz
Offner, Fritz
Trneny, Marek
Wu, Shang-Ju
Cartron, Guillaume
Hertzberg, Mark
Sureda, Anna
Perez-Callejo, David
Lundberg, Linda
Relf, James
Clark, Emma
Humphrey, Kathryn
Hutchings, Martin
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S435 - S435

← 1 2 3 4 5 →